Comparison of resistance to third-generation cephalosporins in Shigella between Europe-America and Asia-Africa from 1998 to 2012

Epidemiology and Infection

Volumn 143, Issue 13, 2015, Pages 2687-2699

  Gu, B ^a,b   Zhou, M ^a,b   Ke, X ^a,b   Pan, S ^a,b   Cao, Y ^a,b   Huang, Y ^a,b   Zhuang, L ^c   Liu, G ^a,b   Tong, M ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b National Key Clinical Department of Laboratory Medicine   (China)

^c JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Cefotaxime; ceftazidime; ceftriaxone; meta analysis; resistance; Shigella flexneri; Shigella sonnei

Indexed keywords

CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARGENTINA; BACTERIAL STRAIN; BAHRAIN; BANGLADESH; BRAZIL; CANADA; CENTRAL AFRICAN REPUBLIC; CHILE; CHINA; COMPARATIVE STUDY; EGYPT; ETHIOPIA; FINLAND; GHANA; GREECE; HUMAN; INDIA; INDONESIA; IRAN; ISRAEL; JAPAN; KOREA; KUWAIT; MALAYSIA; META ANALYSIS; MOZAMBIQUE; NEPAL; NIGERIA; PAKISTAN; PALESTINE; PERU; PREVALENCE; REVIEW; SAUDI ARABIA; SENEGAL; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SOUTH AFRICA; SUDAN; SYSTEMATIC REVIEW; TANZANIA; TREND STUDY; TUNISIA; TURKEY (REPUBLIC); UNITED ARAB EMIRATES; UNITED KINGDOM; UNITED STATES; URUGUAY; VIET NAM; YEMEN; AFRICA; ASIA; DRUG EFFECTS; DYSENTERY, BACILLARY; EUROPE; MICROBIAL SENSITIVITY TEST; SHIGELLA; WESTERN HEMISPHERE;

AFRICA; AMERICAS; ASIA; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; DYSENTERY, BACILLARY; EUROPE; HUMANS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; SHIGELLA;

EID: 84941025199     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268814003446     Document Type: Review

References (55)

1. Niyogi SK, Mitra U, Dutta P. Changing patterns of serotypes and antimicrobial susceptibilities of Shigella species isolated from children in Calcutta, India. Japanese Journal of Infectious Disease. 2001; 54: 121-122.
2. Vinh H, et al. A changing picture of shigellosis in southern Vietnam: shifting species dominance, antimicrobial susceptibility and clinical presentation. BMC Infectious Disease. 2009; 9: 204.
3. Jamsheer AE, et al. Trend of antibiotic resistance in. 1316 Shigella strains isolated in Bahrain. Saudi Medical Journal. 2003; 24: 424-426.
4. Chompook P, et al. Estimating the burden of shigellosis in Thailand: 36-month population-based surveillance study. Bulletin of the World Health Organization. 2005; 83: 739-746.
5. Yang HCG, et al. Surveillance of antimicrobial susceptibility patterns among Shigella species isolated in China during the 7-year period of. 2005-2011. Annals of Laboratory Medicine. 2013; 33: 111-115.
6. Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between. 1992 and. 2000. Bulletin of the World Health Organization. 2003; 81: 197-204.
7. Bryce J, et al. WHO estimates of the causes of death in children. Lancet. 2005; 365: 1147-1152.
8. Kotloff KL, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bulletin of the World Health Organization. 1999; 77: 651-666.
9. WHO. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type. Geneva: World Health Organization
10. Sur D, et al. Shigellosis: challenges and management issues. Indian Journal of Medical Research. 2004; 120: 454-462.
11. Bhattacharya SK, Sur D. An evaluation of current shigellosis treatment. Expert Opinion in Pharmacotherapy. 2003; 4: 1315-1320.
12. Watanabe T. Infective heredity of multiple drug resistance in bacteria. Bacteriological Reviews. 1963; 27: 87-115.
13. Sack RB, et al. Antimicrobial resistance in organisms causing diarrheal disease. Clinical Infectious Disease. 1997; 24 (Suppl. 1): S102-S105.
14. Bhattacharya K, et al. Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children. Acta Paediatrica. 1997; 86: 319-320.
15. Green S TG, Tilloston G. Use of Ciprofloxacinrofloxacin in developing countries. Pediatric Infectious Disease Journal. 1997; 16: 150-159.
16. Gu B, et al. Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe-America and Asia-Africa from. 1998 to. 2009. International Journal of Antimicrobial Agents. 2012; 40: 9-17.
17. Gu B, et al. Prevalence and trends monitoring of aminoglycoside resistance in Shigella worldwide, 1999-2010. Journal of Biomedical Research. 2013; 27: 103-115.
18. Fortineau N, et al. SHV-Type extended spectrumlactamase in a Shigella flexneri clinical isolate. Journal of Antimicrobial Chemotherapy. 2001; 47: 685-688.
19. Rahman M, et al. Extended-spectrum beta-lactamasemediated third-generation cephalosporin resistance in Shigella isolates in Bangladesh. Journal of Antimicrobial Chemotherapy. 2004; 54: 846-847.
20. Goel N, et al. Emergence of ceftriaxone resistant Shigella. Indian Journal of Pediatrics. 2013; 80: 70-71.
21. Vinh H, et al. Rapid emergence of third-generation cephalosporin resistant Shigella spp. in Southern Vietnam. Journal of Medical Microbiology. 2009; 58: 281-283.
22. Taneja N, et al. Cephalosporin-resistant Shigella flexneri over 9 years (2001-09) in India. Journal of Antimicrobial Chemotherapy. 2012; 67: 1347-1353.
23. Freeman MF TJ. Transformations related to the angular and square root. Annals of the Institute of Statistical Mathematics. 1950; 21: 607-611.
24. Tiruneh M. Serodiversity and antimicrobial resistance pattern of Shigella isolates at Gondar University teaching hospital, Northwest Ethiopia. Japanese Journal of Infectious Disease. 2009; 62: 93-97.
25. Opintan J, Newman MJ. Distribution of serogroups and serotypes of multiple drug resistant Shigella isolates. Ghana Medical Journal. 2007; 41: 8-29.
26. Djie-Maletz A RK, et al. High rate of resistance to locally used antibiotics among enteric bacteria from children in Northern Ghana. Journal of Antimicrobial Chemotherapy. 2008; 61: 1315-1318.
27. Bonkoungou IJ, et al. Bacterial and viral etiology of childhood diarrhea in Ouagadougou, Burkina Faso. BMC Pediatrics. 2013; 13: 36.
28. Varsano I, et al. Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. Journal of Pediatrics. 1991;118:627-632
29. Seidlein LV KD, Ali M. A multicentre study of shigella diarrhea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Medicine. 2006; 3: e353.
30. Srinivasa H, Baijayanti M, Raksha Y. Magnitude of drug resistant Shigellosis: a report from Bangalore. Indian Journal of Medical Microbiology. 2009; 27: 358-360.
31. Bradford PA. Extended-spectrumb-lactamases in the 21st century: characterisation, epidemiology and detection of this important resistant threat. Clinical Microbiology Reviews. 2001; 14: 933-951.
32. Lee W, et al. CTX-M-55-Type extended-spectrum beta-lactamase-producing Shigella sonnei isolated from a Korean patient who had travelled to China. Annals of Laboratory Medicine. 2013; 33: 141-144.
33. Marchou B. Travelers diarrheoa: epidemiology, clinical practice guideline for the prevention and treatment. Presse Medicale. 2013; 42: 76-81.
34. Jeon YL, et al. Quinolone-resistant Shigella flexneri isolated in a patient who travelled to India. Annals of Laboratory Medicine. 2012; 32:366-369.
35. Takeshita N. Travellers and multi-drug resistance bacteria. Nihon Rinsho. 2012; 70: 324-328.
36. Mache AMY, Cowly S. Shigella serogroups identified from adult diarrhoea out-patients in Addis Ababa, Ethiopia: antibiotic resistance and plasmid profile analysis. East African Medical Journal. 1997; 74: 179-182.
37. Zhang CL, et al. Drug resistance and molecular epidemiology of Shigella isolated from children with diarrhea. Zhonghua Er Ke Za Zhi. 2012; 50: 777-781.
38. Mariani-Kurkdjian P, Doit C, Bingen E. Extendedspectrum beta-lactamase producing-enterobacteria. Arch Pediatrics. 2012; 19 (Suppl. 3): S93-96.
39. Partridge SR, et al. Gene cassettes and cassette arrays in mobile resistance integrons. FEMS Microbiology Reviews. 2009; 33: 757-784.
40. Perez-Moreno MO, et al. Beta-Lammases, transferable quinolone resistance determinants, and class 1 integronmediated antimicrobial resistance in human clinical Salmonella enteric isolates of non-Typhimurium serotypes. International Journal of Medical Microbiology. 2013; 303: 25-31.
41. Ke X, et al. Epidemiology and molecular mechanism of integron-mediated antibiotic resistance in Shigella. Archives of Microbiology. 2011; 193: 767-774.
42. Sack DA HA, Huq A, Etheridge M. Is protection against shigellosis induced by natural infection with Pleonasms shigellosis?. Lancet. 1994; 343: 1413-1415.
43. Genobile D, et al. An outbreak of shigellosis in a child care center. Communicable Disease Intelligence Quarterly Report. 2004; 28: 225-229.
44. Lewis HC, et al. Outbreaks of Shigella sonnei infections in Denmark and Australia linked to consumption of imported raw baby corn. Epidemiology and Infection. 2009; 137: 326-334.
45. Cohen D, et al. Reduction of transmission of shigellosis by control of houseflies (Musca domestica). Lancet. 1991; 337: 993-997.
46. Holt KE, et al. Shigella sonnei genome sequencing and phylogenetic analysis indicate recent global dissemination from Europe. Nature Genetics. 2012; 44: 1056-1059.
47. Yang H, et al. Serotype distribution and characteristics of antimicrobial resistance in Shigella isolated from Henan province, China, 2001-2008. Epidemiology and Infection. 2013; 141: 1946-1952.
48. Kaminski RW, Oaks EV. Inactivated and subunit vaccines to prevent shigellosis. Expert Review of Vaccines. 2009; 8: 1693-1704.
49. Martinez-Becerra FJ, et al. Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Infection and Immunity. 2012; 80: 1222-1231.
50. Steele D, et al. Vaccines for enteric diseases: a meeting summary. Expert Review of Vaccines. 2012; 11: 407-409.
51. Levine MM, et al. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nature Reviews Microbiology. 2007; 5: 540-553.
52. Osorio M, Bray MD, Walker RI. Vaccine potential for inactivated shigellae. Vaccine. 2007; 25: 1581-1592.
53. Ngado TT, et al. Antibiotic sales in rural and urban pharmacies in northern Vietnam: an observational study. BMC Pharmacology and Toxicology. 2014; 15: 6.
54. Wirtz VJ, et al. Analysing policy interventions to prohibit over-The-counter antibiotic sales in four Latin American countries. Tropical Medicine and International Health. 2013; 18: 665-673.
55. Du HC, John DN, Walker R. An investigation of prescription and over-The-counter supply of opthalmic chloramphenicol in Wales in the 5 years following reclassification. International Journal of Pharmacy Practice. 2014; 22: 20-27.